Biosimilars market size to increase by USD 42,227.12 million: Europe to contribute 46% of market growth - Technavio

News provided by

Dec 08, 2022, 18:30 ET

NEW YORK, Dec. 8, 2022 /PRNewswire/ -- The Biosimilars Market by Product Type, Application, and Geography - Forecast and Analysis 2023-2027 report has been published by Technavio. Market size is forecast to grow by USD 42,227.12 million at a CAGR of 23% between 2022 and 2027. The report provides a comprehensive analysis of growth opportunities at regional levels, new product launches, the latest trends, and the post-pandemic recovery of the global market. Download A PDF Sample Report

Regional Analysis

Technavio has announced its latest market research report titled Global Biosimilars Market 2023-2027

By region, the global biosimilars market is segmented into Europe, North America, Asia, and the Rest of World (ROW). Europe is estimated to contribute 46% to the growth of the global market over the forecast period. The expected approval of multiple biosimilars for blockbuster drugs like Lantus, HUMIRA, Neulasta, Herceptin, and REMICADE, which are currently under review by the EMA, the resumption of paused research studies, and the launch of new biosimilars are driving the growth of the regional market.

Company Profiles

The biosimilars market report includes information on the key products and recent developments of leading vendors, including:

AbbVie Inc.: The company offers biosimilars under the brand Humira.
Amgen Inc.: The company offers biosimilar services such as extrapolation and clinical trials.
Biocon Ltd.: The company offers biosimilars such as Insulin Glargine, Rh-insulin, and Insulin Glargine Disposable Pen.
Biogen Inc.: The company offers biosimilars for Ophthalmology and Immunology.
Boehringer Ingelheim International GmbH
Celltrion Healthcare Co. Ltd.
Dr Reddys Laboratories Ltd.
F. Hoffmann La Roche Ltd.
To gain access to more vendor profiles available with Technavio, buy the report!

Market Dynamics

The market is driven by factors such as the price advantage of biosimilars over biologics, the patent expiry of major biologics, and government initiatives to increase the use of biosimilar medicines. However, the access barriers for biosimilars are hindering market growth.

Competitive Analysis

The competitive scenario categorizes companies based on various performance indicators. Some of the factors considered include the financial performance of companies over the past few years, growth strategies, product innovations, new product launches, investments, and growth in market share, among others. Request a Sample

Market Segmentation

By product type, the market is segmented into monoclonal antibodies, insulin, human growth hormone, and others. The monoclonal antibodies segment accounted for the largest share of the market in 2022.
By geography, the market is segmented into Europe, North America, Asia, and the Rest of the World (ROW). Europe held the largest share of the market in 2022.

Related Reports:

The biosimilar monoclonal antibodies (mAbs) market size is expected to increase by USD 8.65 billion from 2020 to 2025, and the market's growth momentum will accelerate at a CAGR of 30.17%. The increasing prevalence of chronic diseases is notably driving the biosimilar monoclonal antibodies (mAbs) market growth, although factors such as the presence of stringent regulatory policies may impede the market growth.
The human insulin drugs market size in Brazil is expected to increase by USD 137.41 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 5.44%. The rising prevalence of diabetes in Brazil is notably driving the human insulin drugs market growth in Brazil, although factors such as the high cost of human insulin drugs may impede the market growth.

Technavio's library includes over 17,000+ reports, covering more than 2,000 emerging technologies. Subscribe to our "Basic Plan" at just USD 5,000 and get lifetime access to Technavio Insights

What are the key data covered in this biosimilars market report?

CAGR of the market during the forecast period.
Detailed information on factors that will drive the growth of the market between 2023 and 2027
Precise estimation of the biosimilars market size and contribution of the market in focus to the parent market.
Accurate predictions about upcoming trends and changes in consumer behavior.
Growth of the market industry across Europe, North America, Asia, and Rest of World (ROW).
Thorough analysis of the market's competitive landscape and detailed information about vendors.
Comprehensive analysis of factors that will challenge the growth of biosimilar market vendors.

Biosimilars Market Scope
Report Coverage	Details
Page number	172
Base year	2022
Historic period	2017-2021
Forecast period	2023-2027
Growth momentum & CAGR	Accelerate at a CAGR of 23%
Market growth 2023-2027	USD 42227.12 million
Market structure	Fragmented
YoY growth 2022-2023 (%)	22.9
Regional analysis	Europe, North America, Asia, and Rest of World (ROW)
Performing market contribution	Europe at 46%
Key countries	US, Germany, UK, China, and Republic of Korea
Competitive landscape	Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks
Key companies profiled	AbbVie Inc., Amgen Inc., Biocon Ltd., Biogen Inc., Boehringer Ingelheim International GmbH, Celltrion Healthcare Co. Ltd., Dr Reddys Laboratories Ltd., F. Hoffmann La Roche Ltd., Fresenius SE and Co. KGaA, Gedeon Richter Plc, Halozyme Therapeutics Inc, Intas Pharmaceuticals Ltd., Mabion S.A., Novartis AG, Pfizer Inc., Samsung Biologics Co. Ltd., Sanofi SA, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Market dynamics	Parent market analysis, market growth inducers and obstacles, fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period.
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Table of contents:

1 Executive Summary

1.1 Market overview

Exhibit 01: Executive Summary – Chart on Market Overview
Exhibit 02: Executive Summary – Data Table on Market Overview
Exhibit 03: Executive Summary – Chart on Global Market Characteristics
Exhibit 04: Executive Summary – Chart on Market by Geography
Exhibit 05: Executive Summary – Chart on Market Segmentation by Product Type
Exhibit 06: Executive Summary – Chart on Market Segmentation by Application
Exhibit 07: Executive Summary – Chart on Incremental Growth
Exhibit 08: Executive Summary – Data Table on Incremental Growth
Exhibit 09: Executive Summary – Chart on Vendor Market Positioning

2 Market Landscape

2.1 Market ecosystem

Exhibit 10: Parent market
Exhibit 11: Market Characteristics

3 Market Sizing

3.1 Market definition

Exhibit 12: Offerings of vendors included in the market definition

3.2 Market segment analysis

Exhibit 13: Market segments

3.3 Market size 2022

3.4 Market outlook: Forecast for 2022-2027

Exhibit 14: Chart on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 15: Data Table on Global - Market size and forecast 2022-2027 ($ million)
Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)

4 Historic Market Size

4.1 Global biosimilars market 2017 - 2021

Exhibit 18: Historic Market Size – Data Table on Global biosimilars market 2017 - 2021 ($ million)

4.2 Product Segment Analysis 2017 - 2021

Exhibit 19: Historic Market Size – Product Segment 2017 - 2021 ($ million)

4.3 Application Segment Analysis 2017 - 2021

Exhibit 20: Historic Market Size – Application Segment 2017 - 2021 ($ million)

4.4 Geography Segment Analysis 2017 - 2021

Exhibit 21: Historic Market Size – Geography Segment 2017 - 2021 ($ million)

4.5 Country Segment Analysis 2017 - 2021

Exhibit 22: Historic Market Size – Country Segment 2017 - 2021 ($ million)

5 Five Forces Analysis

5.1 Five forces summary

Exhibit 23: Five forces analysis - Comparison between 2022 and 2027

5.2 Bargaining power of buyers

Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027

5.3 Bargaining power of suppliers

Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027

5.4 Threat of new entrants

Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027

5.5 Threat of substitutes

Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027

5.6 Threat of rivalry

Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027

5.7 Market condition

Exhibit 29: Chart on Market condition - Five forces 2022 and 2027

6 Market Segmentation by Product Type

6.1 Market segments

Exhibit 30: Chart on Product Type - Market share 2022-2027 (%)
Exhibit 31: Data Table on Product Type - Market share 2022-2027 (%)

6.2 Comparison by Product Type

Exhibit 32: Chart on Comparison by Product Type
Exhibit 33: Data Table on Comparison by Product Type

6.3 Monoclonal antibodies - Market size and forecast 2022-2027

Exhibit 34: Chart on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 35: Data Table on Monoclonal antibodies - Market size and forecast 2022-2027 ($ million)
Exhibit 36: Chart on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)
Exhibit 37: Data Table on Monoclonal antibodies - Year-over-year growth 2022-2027 (%)

6.4 Insulin - Market size and forecast 2022-2027

Exhibit 38: Chart on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibit 39: Data Table on Insulin - Market size and forecast 2022-2027 ($ million)
Exhibit 40: Chart on Insulin - Year-over-year growth 2022-2027 (%)
Exhibit 41: Data Table on Insulin - Year-over-year growth 2022-2027 (%)

6.5 Human growth hormone - Market size and forecast 2022-2027

Exhibit 42: Chart on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibit 43: Data Table on Human growth hormone - Market size and forecast 2022-2027 ($ million)
Exhibit 44: Chart on Human growth hormone - Year-over-year growth 2022-2027 (%)
Exhibit 45: Data Table on Human growth hormone - Year-over-year growth 2022-2027 (%)

6.6 Others - Market size and forecast 2022-2027

Exhibit 46: Chart on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 47: Data Table on Others - Market size and forecast 2022-2027 ($ million)
Exhibit 48: Chart on Others - Year-over-year growth 2022-2027 (%)
Exhibit 49: Data Table on Others - Year-over-year growth 2022-2027 (%)

6.7 Market opportunity by Product Type

Exhibit 50: Market opportunity by Product Type ($ million)

7 Market Segmentation by Application

7.1 Market segments

Exhibit 51: Chart on Application - Market share 2022-2027 (%)
Exhibit 52: Data Table on Application - Market share 2022-2027 (%)

7.2 Comparison by Application

Exhibit 53: Chart on Comparison by Application
Exhibit 54: Data Table on Comparison by Application

7.3 Oncology and hematology - Market size and forecast 2022-2027

Exhibit 55: Chart on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibit 56: Data Table on Oncology and hematology - Market size and forecast 2022-2027 ($ million)
Exhibit 57: Chart on Oncology and hematology - Year-over-year growth 2022-2027 (%)
Exhibit 58: Data Table on Oncology and hematology - Year-over-year growth 2022-2027 (%)

7.4 Endocrinology - Market size and forecast 2022-2027

Exhibit 59: Chart on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibit 60: Data Table on Endocrinology - Market size and forecast 2022-2027 ($ million)
Exhibit 61: Chart on Endocrinology - Year-over-year growth 2022-2027 (%)
Exhibit 62: Data Table on Endocrinology - Year-over-year growth 2022-2027 (%)

7.5 Immunology - Market size and forecast 2022-2027

Exhibit 63: Chart on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibit 64: Data Table on Immunology - Market size and forecast 2022-2027 ($ million)
Exhibit 65: Chart on Immunology - Year-over-year growth 2022-2027 (%)
Exhibit 66: Data Table on Immunology - Year-over-year growth 2022-2027 (%)

7.6 Nephrology - Market size and forecast 2022-2027

Exhibit 67: Chart on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibit 68: Data Table on Nephrology - Market size and forecast 2022-2027 ($ million)
Exhibit 69: Chart on Nephrology - Year-over-year growth 2022-2027 (%)
Exhibit 70: Data Table on Nephrology - Year-over-year growth 2022-2027 (%)

7.7 Market opportunity by Application

Exhibit 71: Market opportunity by Application ($ million)

8 Customer Landscape

8.1 Customer landscape overview

Exhibit 72: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria

9 Geographic Landscape

9.1 Geographic segmentation

Exhibit 73: Chart on Market share by geography 2022-2027 (%)
Exhibit 74: Data Table on Market share by geography 2022-2027 (%)

9.2 Geographic comparison

Exhibit 75: Chart on Geographic comparison
Exhibit 76: Data Table on Geographic comparison

9.3 Europe - Market size and forecast 2022-2027

Exhibit 77: Chart on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 78: Data Table on Europe - Market size and forecast 2022-2027 ($ million)
Exhibit 79: Chart on Europe - Year-over-year growth 2022-2027 (%)
Exhibit 80: Data Table on Europe - Year-over-year growth 2022-2027 (%)

9.4 North America - Market size and forecast 2022-2027

Exhibit 81: Chart on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 82: Data Table on North America - Market size and forecast 2022-2027 ($ million)
Exhibit 83: Chart on North America - Year-over-year growth 2022-2027 (%)
Exhibit 84: Data Table on North America - Year-over-year growth 2022-2027 (%)

9.5 Asia - Market size and forecast 2022-2027

Exhibit 85: Chart on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 86: Data Table on Asia - Market size and forecast 2022-2027 ($ million)
Exhibit 87: Chart on Asia - Year-over-year growth 2022-2027 (%)
Exhibit 88: Data Table on Asia - Year-over-year growth 2022-2027 (%)

9.6 Rest of World (ROW) - Market size and forecast 2022-2027

Exhibit 89: Chart on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 90: Data Table on Rest of World (ROW) - Market size and forecast 2022-2027 ($ million)
Exhibit 91: Chart on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)
Exhibit 92: Data Table on Rest of World (ROW) - Year-over-year growth 2022-2027 (%)

9.7 Germany - Market size and forecast 2022-2027

Exhibit 93: Chart on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 94: Data Table on Germany - Market size and forecast 2022-2027 ($ million)
Exhibit 95: Chart on Germany - Year-over-year growth 2022-2027 (%)
Exhibit 96: Data Table on Germany - Year-over-year growth 2022-2027 (%)

9.8 US - Market size and forecast 2022-2027

Exhibit 97: Chart on US - Market size and forecast 2022-2027 ($ million)
Exhibit 98: Data Table on US - Market size and forecast 2022-2027 ($ million)
Exhibit 99: Chart on US - Year-over-year growth 2022-2027 (%)
Exhibit 100: Data Table on US - Year-over-year growth 2022-2027 (%)

9.9 UK - Market size and forecast 2022-2027

Exhibit 101: Chart on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 102: Data Table on UK - Market size and forecast 2022-2027 ($ million)
Exhibit 103: Chart on UK - Year-over-year growth 2022-2027 (%)
Exhibit 104: Data Table on UK - Year-over-year growth 2022-2027 (%)

9.10 China - Market size and forecast 2022-2027

Exhibit 105: Chart on China - Market size and forecast 2022-2027 ($ million)
Exhibit 106: Data Table on China - Market size and forecast 2022-2027 ($ million)
Exhibit 107: Chart on China - Year-over-year growth 2022-2027 (%)
Exhibit 108: Data Table on China - Year-over-year growth 2022-2027 (%)

9.11 Republic of Korea - Market size and forecast 2022-2027

Exhibit 109: Chart on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibit 110: Data Table on Republic of Korea - Market size and forecast 2022-2027 ($ million)
Exhibit 111: Chart on Republic of Korea - Year-over-year growth 2022-2027 (%)
Exhibit 112: Data Table on Republic of Korea - Year-over-year growth 2022-2027 (%)

9.12 Market opportunity by geography

Exhibit 113: Market opportunity by geography ($ million)

10 Drivers, Challenges, and Trends

10.1 Market drivers

10.2 Market challenges

10.3 Impact of drivers and challenges

Exhibit 114: Impact of drivers and challenges in 2022 and 2027

10.4 Market trends

11 Vendor Landscape

11.1 Overview

11.2 Vendor landscape

Exhibit 115: Overview on Criticality of inputs and Factors of differentiation

11.3 Landscape disruption

Exhibit 116: Overview on factors of disruption

11.4 Industry risks

Exhibit 117: Impact of key risks on business

12 Vendor Analysis

12.1 Vendors covered

Exhibit 118: Vendors covered

12.2 Market positioning of vendors

Exhibit 119: Matrix on vendor position and classification

12.3 AbbVie Inc.

Exhibit 120: AbbVie Inc. - Overview
Exhibit 121: AbbVie Inc. - Product / Service
Exhibit 122: AbbVie Inc. - Key offerings

12.4 Amgen Inc.

Exhibit 123: Amgen Inc. - Overview
Exhibit 124: Amgen Inc. - Product / Service
Exhibit 125: Amgen Inc. - Key offerings

12.5 Biocon Ltd.

Exhibit 126: Biocon Ltd. - Overview
Exhibit 127: Biocon Ltd. - Business segments
Exhibit 128: Biocon Ltd. - Key offerings
Exhibit 129: Biocon Ltd. - Segment focus

12.6 Biogen Inc.

Exhibit 130: Biogen Inc. - Overview
Exhibit 131: Biogen Inc. - Product / Service
Exhibit 132: Biogen Inc. - Key offerings

12.7 Boehringer Ingelheim International GmbH

Exhibit 133: Boehringer Ingelheim International GmbH - Overview
Exhibit 134: Boehringer Ingelheim International GmbH - Business segments
Exhibit 135: Boehringer Ingelheim International GmbH - Key news
Exhibit 136: Boehringer Ingelheim International GmbH - Key offerings
Exhibit 137: Boehringer Ingelheim International GmbH - Segment focus

12.8 Celltrion Healthcare Co. Ltd.

Exhibit 138: Celltrion Healthcare Co. Ltd. - Overview
Exhibit 139: Celltrion Healthcare Co. Ltd. - Product / Service
Exhibit 140: Celltrion Healthcare Co. Ltd. - Key offerings

12.9 Dr Reddys Laboratories Ltd.

Exhibit 141: Dr Reddys Laboratories Ltd. - Overview
Exhibit 142: Dr Reddys Laboratories Ltd. - Business segments
Exhibit 143: Dr Reddys Laboratories Ltd. - Key offerings
Exhibit 144: Dr Reddys Laboratories Ltd. - Segment focus

12.10 F. Hoffmann La Roche Ltd.

Exhibit 145: F. Hoffmann La Roche Ltd. - Overview
Exhibit 146: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 147: F. Hoffmann La Roche Ltd. - Key news
Exhibit 148: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 149: F. Hoffmann La Roche Ltd. - Segment focus

12.11 Fresenius SE and Co. KGaA

Exhibit 150: Fresenius SE and Co. KGaA - Overview
Exhibit 151: Fresenius SE and Co. KGaA - Business segments
Exhibit 152: Fresenius SE and Co. KGaA - Key news
Exhibit 153: Fresenius SE and Co. KGaA - Key offerings
Exhibit 154: Fresenius SE and Co. KGaA - Segment focus

12.12 Gedeon Richter Plc

Exhibit 155: Gedeon Richter Plc - Overview
Exhibit 156: Gedeon Richter Plc - Business segments
Exhibit 157: Gedeon Richter Plc - Key news
Exhibit 158: Gedeon Richter Plc - Key offerings
Exhibit 159: Gedeon Richter Plc - Segment focus

12.13 Halozyme Therapeutics Inc

Exhibit 160: Halozyme Therapeutics Inc - Overview
Exhibit 161: Halozyme Therapeutics Inc - Product / Service
Exhibit 162: Halozyme Therapeutics Inc - Key offerings

12.14 Intas Pharmaceuticals Ltd.

Exhibit 163: Intas Pharmaceuticals Ltd. - Overview
Exhibit 164: Intas Pharmaceuticals Ltd. - Product / Service
Exhibit 165: Intas Pharmaceuticals Ltd. - Key offerings

12.15 Mabion S.A.

Exhibit 166: Mabion S.A. - Overview
Exhibit 167: Mabion S.A. - Product / Service
Exhibit 168: Mabion S.A. - Key offerings

12.16 Novartis AG

Exhibit 169: Novartis AG - Overview
Exhibit 170: Novartis AG - Business segments
Exhibit 171: Novartis AG - Key offerings
Exhibit 172: Novartis AG - Segment focus

12.17 Viatris Inc.

Exhibit 173: Viatris Inc. - Overview
Exhibit 174: Viatris Inc. - Business segments
Exhibit 175: Viatris Inc. - Key offerings
Exhibit 176: Viatris Inc. - Segment focus

13 Appendix

13.1 Scope of the report

13.2 Inclusions and exclusions checklist

Exhibit 177: Inclusions checklist
Exhibit 178: Exclusions checklist

13.3 Currency conversion rates for US$

Exhibit 179: Currency conversion rates for US$

13.4 Research methodology

Exhibit 180: Research methodology
Exhibit 181: Validation techniques employed for market sizing
Exhibit 182: Information sources

13.5 List of abbreviations

Exhibit 183: List of abbreviations

About Us

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions. With over 500 specialized analysts, Technavio's report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio's comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contact

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/

SOURCE Technavio